Development of ciclesonide analogues that block SARS-CoV-2 RNA replication.
Bioorg Med Chem Lett
; 43: 128052, 2021 07 01.
Article
in English
| MEDLINE | ID: covidwho-1196690
ABSTRACT
Ciclesonide is an inhaled corticosteroid used to treat asthma and is currently undergoing clinical trials for treatment of coronavirus disease 2019 (COVID-19). An active metabolite of ciclesonide, Cic2, was recently reported to repress severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) genomic RNA replication. Herein, we designed and synthesized a few types of ciclesonide analogues. Cic4 (bearing an azide group) and Cic6 (bearing a chloro group) potently decreased SARS-CoV-2 viral replication and had low cytotoxicity compared with Cic2 (bearing a hydroxy group). These compounds are promising as novel therapeutic agents for COVID-19 that show significant antiviral activity.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pregnenediones
/
RNA, Viral
/
SARS-CoV-2
/
COVID-19 Drug Treatment
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Bioorg Med Chem Lett
Journal subject:
Biochemistry
/
Chemistry
Year:
2021
Document Type:
Article
Affiliation country:
J.bmcl.2021.128052
Similar
MEDLINE
...
LILACS
LIS